Back to search

Peptide record

TPDB03529

SB-37 AC Antibacterial Anticancer Antifungal Antiparasitic Toxicity standard
38 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB03529
SB-37 AC
Antibacterial Anticancer Antifungal Antiparasitic Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 Peptipedia ACP740 _ACP240 AntiCP 2.0 CancerPPD 2.0 SATPdb iACP-DRLF pep-lab Antifungipept CAFPdb dbAMP i2APP
standard
No
A 38-aa standard natural multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, Peptipedia, ACP740 _ACP240, and other sources, with an available 3D structural model.
Sequence
MPKWKVFKKIEKVGRNIRNGIVKAGPAIAVLGEAKALG
Physicochemical Analysis
C188H320N54O45S1
DCQHSTY
K
4089.00
11.23
9
2
18
+7
8.24
-0.008
105.26
Mammalian: 30 hour Yeast: >20 hour E.coli: >10 hour
5500
134.51
2
Residue Composition
number
5
A
2
R
2
N
0
D
0
C
2
E
0
Q
5
G
0
H
4
I
2
L
7
K
1
M
1
F
2
P
0
S
0
T
1
W
0
Y
4
V
Amino Acid Distribution
A: 5 R: 2 N: 2 D: 0 C: 0 E: 2 Q: 0 G: 5 H: 0 I: 4 L: 2 K: 7 M: 1 F: 1 P: 2 S: 0 T: 0 W: 1 Y: 0 V: 4
Chemical Descriptors
38
C188H320N54O45S1
4089.00
11.23
+7
8.24
-0.008
Free
L
Linear
Free
Anticancer
FLAK peptides
Evidence Records 10 records
Evidence 1 Activity

Activity

LD50
LD50 =175 µg/ml
Anticancer
175 µg/mL

Target

Breast Cancer
MCF-7
Breast

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 SATPdb
CancerPPD2
2005
US_06875744_B2

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

LD50
LD50 =82 µg/ml
Anticancer
82 µg/mL

Target

Colon Cancer
SW-480
Colon

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 SATPdb
CancerPPD2
2005
US_06875744_B2
Evidence 3 Activity

Activity

LD50
LD50 =120 µg/ml
Anticancer
120 µg/mL

Target

Skin Cancer
BMKC
Skin

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 SATPdb
CancerPPD2
2005
US_06875744_B2
Evidence 4 Activity

Activity

LD50
LD50 =220 µg/ml
Anticancer
220 µg/mL

Target

Lung Cancer
H-1299
Lung

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 SATPdb
CancerPPD2
2005
US_06875744_B2
Evidence 5 Activity

Activity

Not Available
Anticancer

Target

Prostate Cancer
PC-3
Prostate

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 SATPdb
CancerPPD2
2005
US_06875744_B2
Evidence 6 Activity

Activity

LD50
LD50 =150 µg/ml
Anticancer
150 µg/mL

Target

Cervical Cancer
HeLa
Cervix

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 SATPdb
CancerPPD2
2005
US_06875744_B2
Evidence 7 Activity

Activity

LD50
Toxicity
130 µg/mL
Cytotoxic
LD50 | 130 | µg/mL | target cell: Human fibroblasts WI-38

Target

Human fibroblasts WI-38

Source & Reference

NA
DBAASP
Short bioactive peptides | PATENT US 6875744B2 | 2005
Evidence 8 Activity

Activity

50% Hemolysis
Toxicity
>1000 µg/mL
Hemolytic Cytotoxic
50% Hemolysis | >1000 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Short bioactive peptides | PATENT US 6875744B2 | 2005
Evidence 9 Activity

Activity

LD50
Toxicity
950 µg/mL
Cytotoxic
LD50 | 950 | µg/mL | target cell: Human fibroblasts WI-38

Target

Human fibroblasts WI-38

Source & Reference

NA
DBAASP
Short bioactive peptides | PATENT US 6875744B2 | 2005
Evidence 10 Activity

Activity

LD50
Toxicity
>500 µg/mL
Cytotoxic
LD50 | >500 | µg/mL | target cell: Human leukocytes

Target

Human leukocytes

Source & Reference

NA
DBAASP
Short bioactive peptides | PATENT US 6875744B2 | 2005